Anton Drollmann

1.4k total citations
32 papers, 981 citations indexed

About

Anton Drollmann is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology. According to data from OpenAlex, Anton Drollmann has authored 32 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 17 papers in Physiology and 5 papers in Pharmacology. Recurrent topics in Anton Drollmann's work include Asthma and respiratory diseases (17 papers), Inhalation and Respiratory Drug Delivery (13 papers) and Respiratory and Cough-Related Research (9 papers). Anton Drollmann is often cited by papers focused on Asthma and respiratory diseases (17 papers), Inhalation and Respiratory Drug Delivery (13 papers) and Respiratory and Cough-Related Research (9 papers). Anton Drollmann collaborates with scholars based in Switzerland, United States and United Kingdom. Anton Drollmann's co-authors include W Wurst, R. Nave, Hartmut Derendorf, Franklin Cerasoli, Ruediger Nave, Andrew G. Salmon, Steve Newman, Thomas D. Bethke, Sanjeev Khindri and Jan W. De Backer and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Radiology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Anton Drollmann

29 papers receiving 923 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anton Drollmann Switzerland 14 828 693 83 34 28 32 981
Gianluigi Poli Italy 14 520 0.6× 380 0.5× 12 0.1× 14 0.4× 38 1.4× 40 633
Eva Bondesson Sweden 14 566 0.7× 316 0.5× 11 0.1× 10 0.3× 67 2.4× 28 653
Amisha Singapuri United Kingdom 16 538 0.6× 583 0.8× 72 0.9× 57 1.7× 106 3.8× 39 827
Sherif Gonem United Kingdom 14 468 0.6× 499 0.7× 75 0.9× 33 1.0× 30 1.1× 35 753
F Ruff France 10 273 0.3× 104 0.2× 29 0.3× 20 0.6× 34 1.2× 42 534
V H Mak United Kingdom 6 443 0.5× 241 0.3× 10 0.1× 7 0.2× 12 0.4× 8 506
Andrea Segreti Italy 15 501 0.6× 396 0.6× 18 0.2× 66 1.9× 56 2.0× 60 731
SA Kharitonov United States 8 768 0.9× 823 1.2× 48 0.6× 40 1.2× 116 4.1× 9 1.1k
Sabine Häußermann Germany 12 314 0.4× 95 0.1× 5 0.1× 99 2.9× 25 0.9× 22 472
S. Reader United Kingdom 8 220 0.3× 160 0.2× 3 0.0× 16 0.5× 41 1.5× 13 442

Countries citing papers authored by Anton Drollmann

Since Specialization
Citations

This map shows the geographic impact of Anton Drollmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anton Drollmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anton Drollmann more than expected).

Fields of papers citing papers by Anton Drollmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anton Drollmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anton Drollmann. The network helps show where Anton Drollmann may publish in the future.

Co-authorship network of co-authors of Anton Drollmann

This figure shows the co-authorship network connecting the top 25 collaborators of Anton Drollmann. A scholar is included among the top collaborators of Anton Drollmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anton Drollmann. Anton Drollmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Staubach, Petra, Montserrat Álvaro‐Lozano, Bülent Enis Şekerel, et al.. (2023). Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatric Allergy and Immunology. 34(7). e13982–e13982. 12 indexed citations
3.
4.
5.
Singh, Dave, Jim M. Wild, Dinesh Saralaya, et al.. (2022). Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial. Respiratory Research. 23(1). 26–26. 8 indexed citations
6.
Vaidya, Soniya, Brian Ethell, Anton Drollmann, et al.. (2020). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. Pulmonary Pharmacology & Therapeutics. 64. 101964–101964. 9 indexed citations
7.
Drollmann, Anton, et al.. (2013). Glycopyrronium does not affect QT interval in healthy subjects: A randomized, 3-period cross-over, placebo- and positive-controlled study. European Respiratory Journal. 42(Suppl 57). 4634–4634.
8.
Séchaud, Romain, Hisanori Hara, Anton Drollmann, et al.. (2012). Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in man. 40. 4839. 6 indexed citations
9.
Séchaud, Romain, et al.. (2011). Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). International Journal of Clinical Pharmacology and Therapeutics. 50(2). 118–128. 28 indexed citations
10.
Beeh, Kai-Michael, Frank Wagner, Sanjeev Khindri, & Anton Drollmann. (2011). Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD. COPD Journal of Chronic Obstructive Pulmonary Disease. 8(5). 340–345. 56 indexed citations
11.
Khindri, Sanjeev, et al.. (2011). Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulmonary Medicine. 11(1). 31–31. 21 indexed citations
12.
Fogarty, Charles, et al.. (2010). Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respiratory Medicine. 105(3). 337–342. 37 indexed citations
13.
Backer, Jan W. De, Wim Vos, Samir Vinchurkar, et al.. (2010). Validation of Computational Fluid Dynamics in CT-based Airway Models with SPECT/CT. Radiology. 257(3). 854–862. 151 indexed citations
14.
15.
Leach, Chet, Thomas D. Bethke, Robert J. Boudreau, et al.. (2006). Two-Dimensional and Three-Dimensional Imaging Show Ciclesonide Has High Lung Deposition and Peripheral Distribution: A Nonrandomized Study in Healthy Volunteers. Journal of Aerosol Medicine. 19(2). 117–126. 76 indexed citations
16.
Drollmann, Anton, et al.. (2006). Equivalent Pharmacokinetics of the Active Metabolite of Ciclesonide With and Without Use of the AeroChamber Plus??? Spacer for Inhalation. Clinical Pharmacokinetics. 45(7). 729–736. 24 indexed citations
17.
Boulet, LP, Anton Drollmann, Péter Magyar, et al.. (2006). Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respiratory Medicine. 100(5). 785–794. 41 indexed citations
18.
Derendorf, Hartmut, R. Nave, Anton Drollmann, Franklin Cerasoli, & W Wurst. (2006). Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal. 28(5). 1042–1050. 188 indexed citations
19.
Langdon, Cristóbal, et al.. (2005). Once-daily ciclesonide 80 or 320 μg for 12 weeks is safe and effective in patients with persistent asthma. Respiratory Medicine. 99(10). 1275–1285. 47 indexed citations
20.
Drollmann, Anton, et al.. (2004). Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of a spacer for inhalation. Journal of Allergy and Clinical Immunology. 113(2). S120–S120. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gianluigi Poli Breakdown of academic impact, for papers by Eva Bondesson Breakdown of academic impact, for papers by Amisha Singapuri Breakdown of academic impact, for papers by Sherif Gonem Breakdown of academic impact, for papers by F Ruff Breakdown of academic impact, for papers by V H Mak Breakdown of academic impact, for papers by Andrea Segreti Breakdown of academic impact, for papers by SA Kharitonov Breakdown of academic impact, for papers by Sabine Häußermann Breakdown of academic impact, for papers by S. Reader
Rankless by CCL
2026